Organogenesis (ORGO)
(Delayed Data from NSDQ)
$4.50 USD
-0.03 (-0.66%)
Updated Aug 6, 2025 04:00 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ORGO 4.50 -0.03(-0.66%)
Will ORGO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ORGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORGO
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
ORGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
Bioventus (BVS) Matches Q3 Earnings Estimates
Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock
Other News for ORGO
MiMedx price target raised by $1 at Cantor Fitzgerald, here's why
Biggest stock movers Tuesday: NVDA, TTD, STT, WFC and more
Organogenesis (ORGO) Supports New CMS Payment Proposal for 2026 | ORGO Stock News
ORGO: Cantor Fitzgerald Reiterates Overweight Rating with $7 Target | ORGO Stock News
Video: Why Organogenesis And MiMedx Are Sinking Today